0 0 0 -0.0304772857964348 -0.0304772857964348 -0.0225416906267971 -0.0381541115583668 -0.0449108683151236
Sign Up Today X
Thanks for submitting the form.
Stockreport

Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment [Seeking Alpha]

BioMarin Pharmaceutical Inc. (BMRN)  More Company Research Source: Seeking Alpha
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
SummaryBiomarin had its BLA accepted by the FDA for its gene therapy valoctocogene roxaparvovec which is being used to treat patients with severe Hemophilia A.The entire Hemophilia market is estimated to be worth $16.84 billion by 2026, However, Hemophilia A accounts for 80% of all Hemophilia cases.The PDUFA date for FDA review of valoctocogene roxaparvovec for severe Hemophilia A is set for August 21, 2020; For the time being there is no plan for advisory panel.Biomarin has a chance to obtain regulatory approval in Europe for valoctocogene roxaparvovec; The EMA had already accepted the application and is currently under review.BMRNBiologics License Application (BLA) accepted by the FDAAccepted BLA Moves Company Forward In Large MarketThe BLA being accepted for valoctocogene roxaparvovec (valrox) set an FDA first. Another good thing to come out of it would be the first gene therapy to be approved for the treatment of patients with Hemophilia A. Hemophilia A is a Factor VIII (FVIII) de [Read more]
IMPACT SNAPSHOT EVENT TIME: BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BMRN alerts
from News Quantified
BMRN
NEWS
BMRN
Earnings
BMRN
Analyst Actions
BMRN
SEC Filings
Stockreport

Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment [Seeking Alpha]

BioMarin Pharmaceutical Inc.  (BMRN) 
More Company Research Source: Seeking Alpha
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
SummaryBiomarin had its BLA accepted by the FDA for its gene therapy valoctocogene roxaparvovec which is being used to treat patients with severe Hemophilia A.The entire Hemophilia market is estimated to be worth $16.84 billion by 2026, However, Hemophilia A accounts for 80% of all Hemophilia cases.The PDUFA date for FDA review of valoctocogene roxaparvovec for severe Hemophilia A is set for August 21, 2020; For the time being there is no plan for advisory panel.Biomarin has a chance to obtain regulatory approval in Europe for valoctocogene roxaparvovec; The EMA had already accepted the application and is currently under review.BMRNBiologics License Application (BLA) accepted by the FDAAccepted BLA Moves Company Forward In Large MarketThe BLA being accepted for valoctocogene roxaparvovec (valrox) set an FDA first. Another good thing to come out of it would be the first gene therapy to be approved for the treatment of patients with Hemophilia A. Hemophilia A is a Factor VIII (FVIII) de [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS